about
Response to: Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients".Comment on "Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp".Similar Helicobacter pylori Eradication Rate in Obese Patients Undergoing Gastric Bypass Surgery and in General Population.Comment on "Factors Associated with Recurrent Ulcers in Patients with Gastric Surgery after More Than 15 Years: A Cross-Sectional Single-Center Study"Upper GI Bleeding in Cirrhotic Patients: Which Method to Search for Helicobacter Pylori Infection?Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational studyIncreased Liver Enzymes After Gastric Bypass SurgeryRisk factors of suspected spondyloarthritis among inflammatory bowel disease patientsOn-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel DiseasesAdalimumab Therapy Improves Intestinal Dysbiosis in Crohn's DiseaseDoes the Microbiota Play a Pivotal Role in the Pathogenesis of Irritable Bowel Syndrome?Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann IndexHistory of Inflammatory Bowel DiseasesHelicobacter pylori and nonmalignant upper gastrointestinal diseasesEndoscopic Ultrasound-Guided Treatments for Non-Variceal Upper GI Bleeding: A Review of the LiteratureRisk of drug interactions and prescription appropriateness in elderly patientsVedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysisHelicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short reviewInflammation in gastrointestinal disorders: prevalent socioeconomic factorsPrimary Biliary Cholangitis and Bile Acid Farnesoid X Receptor AgonistsIncidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-AnalysisOral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity
P50
Q41027500-A798CBFC-F9F9-40F1-9026-C297830B3524Q48154322-90A3B9AE-D8C2-42A4-8B2C-6760237547BDQ48192203-8C2C5DE3-8F17-45C1-9278-60A863416B22Q60952816-A4834F17-33D2-4062-AC85-27138102794DQ89059736-F4871A52-F75B-43A0-9A0E-3485500267B4Q89698864-010F768C-9883-4420-B130-1D772AAC6603Q90152050-A45484E5-F2B6-4B63-BC15-2D2E8557D1D1Q90252487-3BF4EF4B-0D7E-4769-A212-FC5F4FC7B3DEQ90400913-D56F1C9E-78B4-46DF-A040-EB4C0CB9F86EQ90633465-6C35B104-1A1A-4777-B332-E51FF3DD1E64Q91037025-B68BEED6-25D9-4906-880F-72D259D36805Q91138657-3AAD1E5C-1536-4367-928B-AF1EFC4D3545Q91325104-7A63A24F-FB2E-43B9-A981-BBD25040476DQ91378300-D7F0C20F-3B04-4759-9272-2A4089F75D70Q91548911-A2DE58E8-02FD-4F41-BEA1-B61716EEAEC5Q91575127-E58D5A70-2CF0-47C3-9C1F-7D406368098CQ91862157-DA009629-21D4-430D-9101-1748D596FE9DQ92590090-00082E9D-1C81-45CC-8E49-E985C0324967Q92604098-666AF9E9-E1AA-471B-95F3-E2D34777C470Q96345562-A0EA48E1-4977-4C95-A3E1-F495E936B24BQ96427494-0F2CA692-7F4A-46B1-A25B-60890E2CDE7EQ96603500-AEE9C809-BE52-4777-92D5-0967FA6610D7
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Rinaldo Pellicano
@en
Rinaldo Pellicano
@nl
type
label
Rinaldo Pellicano
@en
Rinaldo Pellicano
@nl
prefLabel
Rinaldo Pellicano
@en
Rinaldo Pellicano
@nl
P31
P496
0000-0003-3438-0649